{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T04:46:58Z","timestamp":1772081218353,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s10637-022-01219-5","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T03:02:16Z","timestamp":1644375736000},"page":"650-659","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of\u00a0central\u00a0nervous system\u00a0lymphoma: a retrospective study"],"prefix":"10.1007","volume":"40","author":[{"given":"Jing-Jing","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan-Shan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-Dong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Nan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song-Tao","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Jie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie-Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Chang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Rui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao-Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei-Fei","family":"Nan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Qin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Yuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3581-551X","authenticated-orcid":false,"given":"Ming-Zhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"1219_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/ppo.0000000000000449","volume":"26","author":"CE Correia","year":"2020","unstructured":"Correia CE, Schaff LR, Grommes C (2020) Central nervous system lymphoma: Approach to diagnosis and treatment. Cancer J 26:241\u2013252. https:\/\/doi.org\/10.1097\/ppo.0000000000000449","journal-title":"Cancer J"},{"key":"1219_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","volume":"23","author":"Y Narita","year":"2021","unstructured":"Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N et al (2021) Phase I\/II study of tirabrutinib, a second-generation Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma. Neuro Oncol 23:122\u2013133. https:\/\/doi.org\/10.1093\/neuonc\/noaa145","journal-title":"Neuro Oncol"},{"key":"1219_CR3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/0284186x.2016.1270465","volume":"56","author":"G Enblad","year":"2017","unstructured":"Enblad G, Martinsson G, Baecklund E, Hesselager G, Sundstr\u00f6m C, Amini RM, Hagberg H (2017) Population-based experience on primary central nervous system lymphoma 2000\u20132012: the incidence is increasing. Acta Oncol 56:599\u2013607. https:\/\/doi.org\/10.1080\/0284186x.2016.1270465","journal-title":"Acta Oncol"},{"key":"1219_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/17474086.2019.1643232","volume":"12","author":"E Santambrogio","year":"2019","unstructured":"Santambrogio E, Nicolosi M, Vassallo F, Castellino A, Novo M, Chiappella A, Vitolo U (2019) Aggressive non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence. Expert Rev Hematol 12:787\u2013796","journal-title":"Expert Rev Hematol"},{"key":"1219_CR5","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.cd-17-0613","volume":"7","author":"C Grommes","year":"2017","unstructured":"Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY et al (2017) Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov 7:1018\u20131029. https:\/\/doi.org\/10.1158\/2159-8290.cd-17-0613","journal-title":"Cancer Discov"},{"key":"1219_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.707285","volume":"11","author":"L Lv","year":"2021","unstructured":"Lv L, Sun X, Wu Y, Cui Q, Chen Y, Liu Y (2021) Efficacy and safety of ibrutinib in central nervous system lymphoma: a prisma-compliant single-arm meta-analysis. Front Oncol 11:707285. https:\/\/doi.org\/10.3389\/fonc.2021.707285","journal-title":"Front Oncol"},{"key":"1219_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1212\/wnl.0000000000003420","volume":"88","author":"K Chamoun","year":"2017","unstructured":"Chamoun K, Choquet S, Boyle E, Houillier C, Larrieu-Ciron D, Al Jijakli A, Delrieu V, Delwail V, Morschhauser F, Hoang-Xuan K et al (2017) Ibrutinib monotherapy in relapsed\/refractory CNS lymphoma: A retrospective case series. Neurology 88:101\u2013102. https:\/\/doi.org\/10.1212\/wnl.0000000000003420","journal-title":"Neurology"},{"key":"1219_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"C Soussain","year":"2019","unstructured":"Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, Bijou F, Houot R, Boyle E, Gressin R et al (2019) Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II \u201cproof-of-concept\u201d iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer 117:121\u2013130. https:\/\/doi.org\/10.1016\/j.ejca.2019.05.024","journal-title":"Eur J Cancer"},{"key":"1219_CR9","doi-asserted-by":"crossref","unstructured":"Lewis KL, Chin CK, Manos K (2021) Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance\/MD Anderson Cancer Center experience. Br J Haematol 192:1049\u20131053. https:\/\/doi.org\/10.1111\/bjh.16946","DOI":"10.1111\/bjh.16946"},{"key":"1219_CR10","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1182\/blood-2019-126305","volume":"134","author":"Y Song","year":"2019","unstructured":"Song Y, Song Y, Liu L, Zhang M, Li Z, Ji C, Xu W, Liu T, Xu B, Wang X et al (2019) Safety and efficacy of orelabrutinib monotherapy in chinese patients with relapsed or refractory mantle cell lymphoma: a multicenter, open-label. Phase II Study Blood 134:755. https:\/\/doi.org\/10.1182\/blood-2019-126305","journal-title":"Phase II Study Blood"},{"key":"1219_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Orelabrutinib: first approval. Drugs 81:503\u2013507. https:\/\/doi.org\/10.1007\/s40265-021-01482-5","journal-title":"Drugs"},{"key":"1219_CR12","unstructured":"Song Y, Song Y, Liu L, Li Z, Ji C, Xu W, Liu T, Xu B, Wang X (2021) Safety and efficacy of orelabrutinib monotherapy in chinese and western patients with b-cell malignancies. In: The 24th National Congress of Clinical Oncology"},{"key":"1219_CR13","doi-asserted-by":"crossref","unstructured":"Xu W, Song Y, Wang T, Yang S, Liu L, Hu Y, Zhang W, Zhou J, Gao S, Ding K (2021) Updated efficacy and safety results of orelabrutinib in the treatment of relapsed or refractory chronic lymphocytic leukemia\/small cell leukemia. Hematol Oncol 39","DOI":"10.1002\/hon.43_2880"},{"key":"1219_CR14","unstructured":"Song Y, Deng L, Zhang B, Luo H, Zhao R (2021) Preliminary results of orelabrutinib concentrations in peripheral blood and cerebrospinal fluid in patients with relapsed\/refractory primary or secondary CNS lymphoma In: The 24th National Congress of Clinical Oncology"},{"key":"1219_CR15","doi-asserted-by":"crossref","unstructured":"Zhu J, Ma J (2021) Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version). Chin J Cancer Res 33:289-301. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2021.03.01.","DOI":"10.21147\/j.issn.1000-9604.2021.03.01"},{"key":"1219_CR16","first-page":"1000","volume":"13","author":"M Li","year":"2015","unstructured":"Li M, Wang Z-A (2015) New advances in the treatment of relapsed\/refractory diffuse large B-cell lymphoma. Chinese J Gen Pract 13:1000\u20131003","journal-title":"Chinese J Gen Pract"},{"key":"1219_CR17","unstructured":"Fridberg J (2011) The American society of hematology education program book. Am Hematol 498\u2013505"},{"key":"1219_CR18","doi-asserted-by":"publisher","unstructured":"Kuitunen H, Kaprio E (2020) Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell\/follicular grade 3B lymphoma. 99:1823\u20131831. https:\/\/doi.org\/10.1007\/s00277-020-04140-0","DOI":"10.1007\/s00277-020-04140-0"},{"key":"1219_CR19","unstructured":"Health UDO, Services H (2019) Common terminology criteria for adverse events (CTCAE) version 5.0. Published November 27, 2017. In"},{"key":"1219_CR20","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1002\/cncr.30965","volume":"123","author":"CH Han","year":"2017","unstructured":"Han CH, Batchelor TT (2017) Diagnosis and management of primary central nervous system lymphoma. Cancer 123:4314\u20134324. https:\/\/doi.org\/10.1002\/cncr.30965","journal-title":"Cancer"},{"key":"1219_CR21","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.6004\/jnccn.2020.7667","volume":"18","author":"M Holdhoff","year":"2020","unstructured":"Holdhoff M, Mrugala MM, Grommes C, Kaley TJ, Swinnen LJ, Perez-Heydrich C, Nayak L (2020) Challenges in the treatment of newly diagnosed and recurrent primary central nervous system lymphoma. J Natl Compr Canc Netw 18:1571\u20131578. https:\/\/doi.org\/10.6004\/jnccn.2020.7667","journal-title":"J Natl Compr Canc Netw"},{"key":"1219_CR22","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1200\/jco.2006.06.6910","volume":"24","author":"IT Gavrilovic","year":"2006","unstructured":"Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570\u20134574. https:\/\/doi.org\/10.1200\/jco.2006.06.6910","journal-title":"J Clin Oncol"},{"key":"1219_CR23","doi-asserted-by":"crossref","unstructured":"Dhillon S (2021) Orelabrutinib: first approval. Drugs 1\u20135","DOI":"10.1007\/s40265-021-01482-5"},{"key":"1219_CR24","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/s2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Ros\u00e9e PL, Schorb E et al (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3:e217-227. https:\/\/doi.org\/10.1016\/s2352-3026(16)00036-3","journal-title":"Lancet Haematol"},{"key":"1219_CR25","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1182\/blood-2019-126305","volume":"134","author":"Y Song","year":"2019","unstructured":"Song Y, Song Y, Liu L, Zhang M, Li Z, Ji C, Xu W, Liu T, Xu B, Wang X (2019) Safety and efficacy of orelabrutinib monotherapy in Chinese patients with relapsed or refractory mantle cell lymphoma: a multicenter, open-label, phase II study. Blood 134:755","journal-title":"Blood"},{"key":"1219_CR26","doi-asserted-by":"publisher","unstructured":"Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, Piotrowski AF, Stone J, Lin A, Nolan CP et al (2019) Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma. 133:436\u2013445. https:\/\/doi.org\/10.1182\/blood-2018-09-875732","DOI":"10.1182\/blood-2018-09-875732"},{"key":"1219_CR27","doi-asserted-by":"publisher","unstructured":"Wu J, Duan L, Zhang L, Sun Z, Fu X, Li X, Li L, Wang X, Zhang X, Li Z et al (2018) Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial. 140:427\u2013434. https:\/\/doi.org\/10.1007\/s11060-018-2970-x","DOI":"10.1007\/s11060-018-2970-x"},{"key":"1219_CR28","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A, Keam SJ (2019) Camrelizumab: first global approval. Drugs 79:1355\u20131361","journal-title":"Drugs"},{"key":"1219_CR29","doi-asserted-by":"crossref","unstructured":"Tam CS, Cull G, Opat S, Gregory GP, Liu A, Johnston AM, Zhao W, Roncolato F, Handunnetti SM, Prince HM (2019) An update on safety and preliminary efficacy of highly specific Bruton tyrosine kinase (BTK) inhibitor zanubrutinib in combination with PD-1 inhibitor tislelizumab in patients with previously treated B-cell lymphoid malignancies. In: American Society of Hematology Washington, DC","DOI":"10.1182\/blood-2019-125485"},{"key":"1219_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2020-138764","volume":"136","author":"L Renaud","year":"2020","unstructured":"Renaud L, Bossard J-B, Terriou L, Cambier N, Chanteau G, Carpentier B, Barbieux S, Wemeau M, Hieulle J, Boyle EM (2020) Treatment with temozolomide and ibrutinib in recurrent\/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Blood 136:23\u201324","journal-title":"Blood"},{"key":"1219_CR31","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.blre.2018.03.003","volume":"32","author":"O Bairey","year":"2018","unstructured":"Bairey O, Siegal T (2018) The possible role of maintenance treatment for primary central nervous system lymphoma. Blood Rev 32:378\u2013386. https:\/\/doi.org\/10.1016\/j.blre.2018.03.003","journal-title":"Blood Rev"},{"key":"1219_CR32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Bri\u00e8re J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u2013242","journal-title":"N Engl J Med"},{"key":"1219_CR33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.omto.2021.03.015","volume":"21","author":"H Yu","year":"2021","unstructured":"Yu H, Wang X, Li J, Ye Y, Wang D, Fang W, Mi L, Ding N, Wang X, Song Y et al (2021) Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma. Mol Ther Oncolytics 21:158\u2013170. https:\/\/doi.org\/10.1016\/j.omto.2021.03.015","journal-title":"Mol Ther Oncolytics"},{"key":"1219_CR34","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.clml.2018.06.016","volume":"18","author":"S O'Brien","year":"2018","unstructured":"O\u2019Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C et al (2018) Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma or mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 18:648-657.e615. https:\/\/doi.org\/10.1016\/j.clml.2018.06.016","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01219-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-022-01219-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01219-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:43:28Z","timestamp":1678509808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-022-01219-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1219"],"URL":"https:\/\/doi.org\/10.1007\/s10637-022-01219-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]},"assertion":[{"value":"19 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of the Affiliated Hospital of Zhengzhou University (2021-KY-0886\u2013002).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Yes.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"The authors declare that they have no conflict of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}